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1) The MeOH extract of its stem bark was reported to have hepatoprotective effects and (ϩ)-rhododendrol (11) was isolated as the active principle.
2) The stem bark is reported to contain various diarylheptanoids and phenolic compounds, [3] [4] [5] and some principal diarylheptanoid constituents have been reported to exhibit inhibitory effects on the release of b-hexosaminidase in RBL-2H3 cells 6) and on the nitric oxide production in lipopolysaccharide-activated macrophages. 7) In the course of our search for potential antitumor promoters from natural sources, 8, 9) we were especially interested to undertake the investigation of A. nikoense. In this paper, we present the isolation and structure elucidation of a new diarylheptanoid of the cyclic biphenyl ether type, 1, along with nine known diarylheptanoids, 2-10, and two known phenolic compounds, 11 and 12, from a MeOH extract of its stem bark, as well as their inhibitory effects on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced inflammation in mice, and on Epstein-Barr virus early antigen (EBV-EA) activation induced by TPA, as primary screenings for anti-tumor promoters. 8, 9) The n-hexane and MeOH extracts of A. nikoense stem bark and the EtOAc-, n-BuOH-, and H 2 O-soluble fractions obtained from the MeOH extract were examined against TPA (1.7 nmol)-induced inflammation in mice and TPA (32 pmol)-induced EBV-EA activation in Raji cells. As shown in Table 1 , the EtOAc-soluble fraction exhibited the most potent inhibitory activities in both assay systems [66% inhibition of inflammation in mice at a dose of 1.0 mg/ear; and 48.5% inhibition of TPA (32 pmol)-induced EBV-EA activation at a dose of 10 mg/ml]. The EtOAc-soluble fraction was further investigated for the active constituents in this study. Chromatography of this fraction on normal-phase and reversed-phase silica gel column and reversed-phase prepara- C-NMR spectrum of 1 ( Table 2 ) exhibited 19 signals assignable to two benzene rings (five singlets and seven doublets), five methylenes, a carbonyl, and an oxymethine carbon. These findings, in combination with its IR spectrum which showed absorption bands at 3389, 1704, 1595, 1517, 1503, and 1053 cm Ϫ1 assignable to hydroxyl, carbonyl, aromatic ring, and ether functions, and its UV spectrum which exhibited an absorption at 278 nm (log e 3.14), suggested that 1 is a biphenyl ether-type cyclic diarylheptanoid. 3, 4) Compound 1 was shown to possess a b-ketol system at C-7 (CϭO) and C-9 (ϾCHOH) in the heptane chain by observation of 13 
C-
1 H long-range couplings from H-4 to C-7, from H-6 to C-7, from H-8 to C-7, from H-10 to C-8, and from H-8, H-10 and H-11 to C-9, in the heteronuclear multiple-quantum coherence (HMBC) spectrum (Fig. 1) . Furthermore, the presence of a hydroxyl group at C-2 was shown by 13 
1 H long-range couplings from H-3, H-4, and H-6 to C-2 observed in the HMBC spectrum of 1. The above evidence coupled with analysis of 1 H-1 H correlation spectroscopy (COSY) (Fig. 1) , 1 H-detected multiple-quantum coherence (HMQC), and HMBC data indicated that 1 possesses a structure as formulated in Chart 1 which has been called acerogenin M.
10) Stereochemistry at C-9 remain undetermined. Comparison of the 13 C-and 1 H-NMR data of 1 with those of the structurally related cyclic diarylheptanoids 4, 5, 7) supported the proposed structure. Identification of nine known compounds, acerogenin A (2), 11) aceroside III (4), 12) (R)-acerogenin B (5), 7) aceroside B 1 (6), 7) aceroside IV (8), 13) acerogenin K (9), 5) (Ϫ)-centrolobol (10), 14) (ϩ)-rhododendrol (11), 15) and (ϩ)-catechin (12), 16) was made by spectral comparison with corresponding compounds in the literature. Two other known compounds, aceroside I (3) 11) and acerogenin D (7), 4) were identified 736 Vol. 54, No. 5 Table 2 . Atom No. based on the MS and NMR spectral analysis since the spectral data were unavailable in the literature. Seven diarylheptanoids, 2-6, 8, and 10, and two phenolic comopounds, 11 and 12, were evaluated with respect to their anti-inflammatory activity against TPA-induced inflammation in mice, and the inhibitory effects were compared with those of quercetin (3,3Ј,4Ј,5,7-pentahydroxyflavone), a known inhibitor of TPA-induced inflammation in mice, and indomethacin, a commercially available anti-inflammatory drug, as shown in Table 3 . All of the diarylheptanoids tested except for compound 3 inhibited the TPA-induced inflammation [ID 50 (50% inhibitory dose) 0.26-0.81 mg/ear], making them more inhibitory than quercetin (ID 50 1.6 mg/ear). Three compounds, 2, 5, and 6, exhibited the strongest inhibitory effects (ID 50 0.26-0.32 mg/ear) among those tested, which being comparable with that of indomethacin (ID 50 0.30 mg/ear). The inhibitory effect against TPA-induced inflammation has been demonstrated to closely parallel that of the inhibition of tumor promotion in two-stage carcinogenesis initiated by 7,12-dimethylbenz[a]anthracene (DMBA) and then by TPA, a well-known promoter, in a mouse skin model. 17) Thus, these diarylheptanoids can be expected to possess a high anti-tumor-promoting effect in the same animal model. Curcumin (diferuloylmethane), [18] [19] [20] [21] [22] the major yellow pigment in turmeric (Curcuma longa L.), and other naturally occurring diarylheptanoids [19] [20] [21] 23, 24) have also been demonstrated to possess marked anti-inflammatory 18, 19, 22, 23) and anti-tumor-promoting effects. 20, 21, 24) The inhibitory effect on EBV-EA activation induced by TPA was further examined as a preliminary evaluation of the potential anti-tumor-promoting effects of the ten diarylheptanoids, 1-10, and the two phenolic compounds, 11 and 12.
The results are shown in Table 3 , together with comparable data for quercetin as well as b-carotene, a vitamin A precursor that has been intensively studied in cancer chemoprevention by using animal models. 25) All of the compounds tested showed inhibitory effects with IC 50 values of 356-534 mol ratio/32 pmol TPA, which were more inhibitory than quercetin (IC 50 560 mol ratio/32 pmol TPA). Among them, three compounds, 9-11, exhibited potent inhibitory effects Chart 
Structures of Compounds 1-12
A conventional numbering system of acerosides 5) was adopted for the cyclic diarylheptanoids. The values of all compounds at 500 mol ratio/TPA were different from the control value (pϽ0.05) without cytotoxicity. e) IC 50 represents the mol ratio to TPA that inhibits 50% of positive control (100%) activated with 32 pmol TPA. f) EBV-EA induction data taken from literature. 21) g) EBV-EA induction data taken from literature. 28) (IC 50 356-392 mol ratio/32 pmol TPA) almost comparable with b-carotene (IC 50 397 mol ratio/32 pmol TPA).
From the results of in vivo anti-inflammatory test and in vitro EBV-EA induction test, it may be suggested that diarylheptanoids from the EtOAc-soluble fraction of the MeOH extract of A. nikoense stem bark are useful as agents that inhibit inflammation and chemical carcinogenesis.
Experimental
Optical rotations were measured on a JASCO P-1030 polarimeter in MeOH at 25°C. UV spectra on a Shimadzu UV-2200 spectrometer and IR spectra on a JASCO FTIR-300E spectrometer were recorded in MeOH and KBr disks, respectively. NMR spectra were recorded with a JEOL ECA-600 spectrometer at 600 MHz ( 1 H-NMR) and 150 MHz ( 13 C-NMR) in C 5 D 5 N with tetramethylsilane as internal standard. EI-MS (70 eV) and HR-EI-MS were recorded on a JEOL JMS-BU20 spectrometer using a direct inlet system. FAB-MS were obtained with a JEOL JMS-BU20 spectrometer using glycerol as a matrix. Silica gel (Silica gel 60, 220-400 mesh, Merck) and C 18 silica (Chromatorex-ODS, 100-200 mesh; Fuji Silysia Chemical, Ltd., Aichi, Japan) were used for open column chromatography. Reversed-phase preparative HPLC was carried out on a C 18 silica column (Pegasil ODS II column, 5 mm; 25 cmϫ10 mm i.d.; Senshu Scientific Co., Ltd., Tokyo, Japan; flow rate of the mobile phase: 3.0 ml/min) at 25°C. A refractive index detector was used for the HPLC. Some spectral data for compounds 1, 3, and 7 are given below. 13 C distortionless enhancement by polarization transfer (DEPT), 1 H-1 H COSY, HMQC, HMBC, and nuclear Overhauser enhancement and exchange spectroscopy (NOESY) experiments were used for structure elucidation and to assign the 13 H-NMR data, see Table 2 .
Animals The experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of the College of Pharmacy, Nihon University, Chiba, Japan. Specific pathogen-free female ICR mice were obtained from Japan SLC (Shizuoka, Japan). The animals were housed, five per polycarbonate cage, in an air-conditioned specific pathogen-free room at 24Ϯ2°C. Food and water were available ad libitum.
Assay of TPA-Induced Inflammation Ear Edema in Mice TPA (1 mg, 1.7 nmol) dissolved in acetone (20 ml) was applied to the right ear of mice by a micropipette. A volume of 10 ml was delivered to both the inner and outer surfaces of the ear. The samples or their vehicles, MeOH-CHCl 3 -H 2 O (2 : 1 : 1, v/v/v; 20 ml) or MeOH-H 2 O (1 : 1, v/v; 20 ml), as control, were applied topically about 30 min before TPA treatment. For ear thickness determinations, a pocket thickness gauge with a range of 0-9 mm, graduated at 0.01 mm intervals and modified so that the contact surface area was increased to reduce the tension, was applied to the tip of the ear. The ear thickness was measured before treatment (a), and 6 h after TPA treatment (bϭTPA alone; bЈϭTPA plus sample). The following values were then calculated: Edema A is induced by TPA alone (bϪa). Edema B is induced by TPA plus sample (bЈϪa). Inhibitory ratio (%)ϭ[(edema AϪedema B)/edema A]ϫ100.
Each value was the mean of individual determinations from five mice. The 50% inhibitory dose (ID 50 ) values were determined by the method of probitgraphic interpolation for four dose levels. A statistical analysis was carried out by Student's t-test. Details of the in vivo anti-inflammatory test have been described previously. 26) In Vitro EBV-EA Activation Experiment The inhibition of EBV-EA activation was assayed using Raji cells (EBV genome-carrying human lymphoblastoid cells; non-producer type), cultivated in 10% fetal bovine serum RPMI-1640 medium (Sigma, St. Louis, MO, U.S.A.). The indicator cells (Raji cells; 1ϫ10 6 cells/ml) were incubated in 1 ml of the medium containing 4 mmol n-butanoic acid as an inducer, 32 pmol of TPA (20 ng/ml in dimethyl sulfoxide), and a known amount (32, 16, 3.2, 0.32 nmol) of the test compound at 37°C in a CO 2 incubator. After 48 h, cell suspensions were centrifuged at 1000 rpm for 10 min, and the supernatant was removed. The activated cells were stained with high-titer EBV-EA-positive sera from nasopharyngeal carcinoma patients, and the conventional indirect immunofluorescence technique was employed for detection. In each assay, at least 500 cells were counted and the experiments were repeated three times. The average extent of EA induction was determined and compared with that on positive control experiments in which the cells were treated with n-butanoic acid plus TPA where the extent of EA induction was ordinarily more than around 40%. The viability of treated Raji cells was assayed by the Trypan Blue staining method. Details of the in vitro assay of EBV-EA induction have been reported previously. 27) 
